# A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer

> **NCT05141357** · PHASE2 · TERMINATED · sponsor: **HUYABIO International, LLC.** · enrollment: 5 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** HBI-8000 in combination with pembrolizumab

## Key facts

- **NCT ID:** NCT05141357
- **Lead sponsor:** HUYABIO International, LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-02-15
- **Primary completion:** 2023-04-19
- **Final completion:** 2023-04-19
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Slow Recruitment
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05141357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05141357, "A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05141357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*